Abubaker Sidahmed
Assistant Professor
MD University of Baghdad
MSc University of Guelph
PhD University of Toronto
D(ABHI) American board of Histocompatibility and Immunogenetics Diplomate certification
Office: LHSC UH, A3-228A
Phone: (519) 685-8500 Ext. 33086
Fax: (519) 663-3687
E-mail: abubaker.sidahmed@lhsc.on.ca
Clinical Activities
Division head, Transplant Immunology, director of Histocompatibility and Immunogenic laboratory.
Keywords: clinical Immunology, Immunogenetics Histocompatibility, Transplant Immunology, Immunopathology
Description of Activities:
- Assess immunological risk for patient/donor pairs waiting for organ or hematopoietic stem cell transplant; Post-transplant risk assessment and diagnosis for rejection;
- Provide consultation to clinicians on patient/donor selection and treatment;
- Develop new assays and ensure testing accurately reported in a timely manner.
Research Activities
Keywords: allotransplantation, BK virus, Allo-HLA tolerance, Innate immunity
Description of Research Activities: Transplantation is one of the definitive life-saving treatments for patients suffering from end stage organ disease or tissue failures. Although tremendous progress has been made to improve the success rate of transplantation, human leukocyte antigen (HLA) and host versus graft/graft versus host-associated immune responses continue to be major difficulties in the setting of allotransplantation. The major roles of the histocompatibility laboratory are to do HLA typing and to identify anti-HLA antibody specificities. Numerous platforms are in use at present to accomplish these objectives. My research interest is to improve the present and to develop additional clinical applicable assays and to look at clinical outcomes based on the interpretation of HLA laboratory testing data.
It is well documented that BK virus infection to renal epithelial cell induce phosphorylation of 3'-phosphoinositide-dependent kinase-1 (PDK-1), the protein kinase Akt, mammalian target of rapamycin (mTOR), and 70 kDa ribosomal protein S6 kinase. I believe that will make these cells immortal and might induce cancer.
I believe that solid organ rejection and GvsHD start with innate immunity. I am interested in investigating the roles of innate immunity in solid organ rejection and GvsHD.
A long-term goal is to study the mechanisms of immune tolerance and targeting to develop approaches to induce allo-HLA tolerance in the transplant recipients.
